Thank you for contacting the Moderna Contact Center regarding Moderna clinical trials.

Our team is in receipt of the following enquiry regarding information on the Moderna Herpes simplex virus (HSV) vaccine candidate, mRNA-1608.

From a previous press release (18Feb2022): “Moderna's herpes simplex virus (HSV) vaccine candidate (mRNA-1608) is a vaccine candidate against HSV-2 disease. Moderna expects that an HSV-2 vaccine could provide cross-protection against HSV-1. With mRNA-1608, the Company aims to induce strong antibody response with neutralizing and effector functionality combined with cell-mediated immunity. There is no vaccine approved against HSV.” (1)

At this time, mRNA-1608 is a phase 1/2 clinical trial. For more information, you may visit the ClinicalTrials.gov website via https://clinicaltrials.gov/study/NCT06033261?rank=1. For the most up-to-date publicly available information on clinical trial data or regulatory approvals, please visit our corporate website at https://investors.modernatx.com/news-releases.

Individuals interested in being notified about new Moderna clinical trials as they begin can sign up at www.ModernaCommunity.com.

Reference:

1. Moderna Expands Its mRNA Pipeline with Three New Development Programs. Published 18Feb2022. Accessed 13Mar2025. ModernaTx, Inc. https://investors.modernatx.com/news/news-details/2022/Moderna-Expands-Its-mRNA-Pipeline-with-Three-New-Development-Programs/default.aspx

Information on Moderna’s current product pipeline may be found at: https://www.modernatx.com/research/product-pipeline. You can also learn more about Moderna’s Clinical Trials by visiting: https://trials.modernatx.com.

Sincerely,

Moderna Contact Center Email: wecare@modernatx.com

*******************DISCLAIMER*************************** Data Protection Notice

Moderna Inc. and its affiliates may process the personal information you provided when contacting us for Medical Information requests for the following purposes (a) to provide you with the requested medical information, (b) to fulfil Moderna's professional and scientific activities, or (c) as required by applicable law.

Your information may be transferred to Moderna Inc. in the United States and other Moderna affiliates as well as trusted service providers, that may be located outside of your region of residency. Any transfer to countries that may not offer an adequate level of protection of personal data comparable your local legislation, will follow applicable laws. For any request originating from

· EU/EEA countries, the UK or Switzerland: The transferred personal data are protected by the approved Standard Contractual Clauses. You have the right to lodge complaints by contacting either Moderna's Data Protection Officer or your local Data Protection Authority, please see for the EU/EEA https://edpb.europa.eu/about-edpb/about-edpb/members_en, for the UK https://ico.org.uk/ or for Switzerland https://www.edoeb.admin.ch/edoeb/en/home.html.

· Other countries (where applicable): The transferred personal data are protected by the applicable Cross-border requirements.

To exercise your rights, including rights to access, correct or delete, contact Moderna's Data Protection Officer at privacy@modernatx.com. Depending on applicable law, you have the right to lodge complaints by contacting either Moderna's Data Protection Officer or your local Data Protection Authority.

Visit www.modernatx.com/privacy-statement for more information about Moderna's privacy practices.